Crucell HIV Vaccine: Promising Preliminary Results Phase I Study
Crucell N.V. announced that preliminary results of the Phase I study of its HIV vaccine were presented at La Conférence AIDS Vaccine 2009 in Paris, France. The presentation was given by Dr Dan H. Barouch, MD, PhD, Associate Professor of medicine, Division of Vaccine Research, Department of Medicine at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, USA. The preliminary results of the Phase I study show that this HIV candidate vaccine is safe and immunogenic.
In April 2008, Crucell announced the start of a Phase I clinical study of the novel recombinant HIV vaccine. The vaccine is based on its AdVac® and PER.C6® technologies, using adenovirus serotype 26 (rAd26) as vector and is jointly developed by Crucell and the BIDMC, funded by a grant from the US National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The rAd26 vector is specifically designed to avoid the pre-existing immunity to the more commonly used adenovirus serotype 5 (Ad5). The Phase I clinical study is being conducted at the Brigham and Women's Hospital in Boston, USA and involves 48 healthy volunteers. Boost vaccinations are ongoing.
"The vaccine is designed to overcome the pre-existing immunity in humans against the most commonly used recombinant vaccine vector, adenovirus serotype 5. These encouraging preliminary results are paving the way for the further development of this vaccine vector for HIV and other pathogens." says Dr Barouch.
Other news from the department research and development
